查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363998

全球生物製藥市場2023-2030

Global Biopharmaceuticals Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

細分市場前景

全球生物製藥市場按產品類型、服務和應用細分。根據產品類型，市場細分為單株抗體、重組生長因子、純化蛋白、疫苗、荷爾蒙、基因療法和其他（干擾素、合成免疫調節劑）。根據服務，市場分為實驗室測試、客戶專有測試以及藥典和多藥典實驗室測試。此外，根據應用，市場細分為腫瘤學、發炎和傳染病、自體免疫疾病、代謝性疾病、心血管疾病、神經系統疾病和其他（荷爾蒙失調）。在這些應用中，由於腫瘤藥物的開發不斷成長，包括標靶治療、化療藥物、免疫療法和荷爾蒙療法等多種藥物，預計腫瘤細分市場將佔據相當大的市場佔有率。癌症。

預計疫苗細分市場將在全球生物製藥市場中佔據相當大的佔有率

在產品類型中，疫苗細分市場預計將在全球生物製藥市場中佔據相當大的佔有率。這一細分市場的成長歸因於疫苗開發過程中奈米技術、基於基因的檢測、下一代定序技術和基因工程的整合的增加，預計將增強新型疫苗類型的革命性潛力。核酸疫苗、mRNA疫苗、載體疫苗和生物材料疫苗是疫苗革命的最新趨勢，因為它們具有解決現有技術問題的潛力。例如，2023年9月，輝瑞公司和BioNTech SE宣布，美國FDA批准了針對12歲及以上個人的補充生物製劑許可申請，​​並為該公司的Omicron XBB授予6個月至11歲個人的緊急使用授權.1.5 適應的單價COVID-19 疫苗。

區域展望

全球生物製藥市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國、亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，亞太地區由於強勁的市場佔有率，預計將在全球市場中佔據顯著佔有率。醫療設施基礎，以及專門針對這些複雜疾病的根本原因的先進治療方案的可用性，改善的治療結果，並加強該地區的患者護理。

北美地區預計全球生物製藥市場年複合成長率顯著成長

在所有地區中，北美地區預計在預測期內將以相當大的年複合成長率成長。區域成長歸因於用於疾病治療的生物製藥的採用和可用性的增加以及疾病診斷意識的提高。隨著經濟成長、醫療保健提供和保險機制的擴大，對本地和進口藥品的需求增加。根據歐洲製藥工業協會聯合會（EFPIA）2022年5月的數據，2021年北美佔全球藥品銷售額的49.1%，而歐洲為23.4%。隨著新興市場擴大應對在更強大的經濟體中已經普遍存在的非傳染性疾病（NCD），包括糖尿病和高血壓，而困擾許多新興市場的傳染性疾病（如後天免疫缺陷綜合症、瘧疾和結核病）持續存在，藥品需求呈現多樣性。全球人口的成長也促進了藥品消費。

市場成長受到多種因素的推動，例如老年人口的增加、癌症和糖尿病等慢性病盛行率的激增以及全球生物製藥採用的增加。此外，預計生物製藥公司之間策略合作的增加也將補充生物製藥產業的成長。主要市場參與者包括艾伯維公司、阿斯特捷利康公司、羅氏公司、默克公司、輝瑞公司等。

市場參與者展望

服務生物製藥市場的主要公司包括羅氏公司、強生公司、艾伯維公司、默克公司、諾華公司、輝瑞公司等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2020 年 10 月，IAVI（一個致力於解決緊迫的、未解決的全球健康挑戰的非營利科學研究組織）和印度血清研究所 Pvt.疫苗和生物製品製造商有限公司宣布與德國達姆施塔特的科技公司默克達成協議，開發新冠病毒 (COVID-19) 中和單株抗體 (mAb)。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球生物製藥市場的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • AbbVie, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Johnson and Johnson Service, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Pfizer, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • F. Hoffman-La Roche, Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按產品類型分類的全球生物製藥市場
    • 單株抗體
    • 重組生長因子
    • 純化蛋白質
    • 疫苗
    • 荷爾蒙
    • 基因療法
    • 其他（干擾素、合成免疫調節劑）
  • 全球生物製藥市場（按服務）
    • 實驗室測試
    • 客戶專有測試
    • 藥典和多藥典實驗室測試
  • 全球生物製藥市場按應用
    • 腫瘤學
    • 發炎和傳染病
    • 自體免疫疾病
    • 代謝紊亂
    • 心血管疾病
    • 神經系統疾病
    • 其他（荷爾蒙失調）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

第 6 章：公司簡介

  • AbbVie Inc.
  • Bayer AG
  • Abbott Laboratories
  • Allergan, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline PlcPharmaceuticals Ltd.
  • McKesson Corp.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Sanofi SA
  • Takeda Pharmaceutical Industries, Ltd.
  • Vertex Pharmaceuticals
Product Code: OMR2027725

Title: Global Biopharmaceuticals Market Size, Share & Trends Analysis Report by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Vaccines, Hormones, Gene Therapies and Others), by Service (Laboratory Testing, Customer Proprietary Testing, Compendial and Multi Compendial Laboratory Testing), and by Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Cardiovascular Diseases, Neurological Diseases and Other),Forecast Period (2023-2030).

Global biopharmaceuticals market is anticipated to grow at a CAGR of 7.2 % during the forecast period (2023-2030). Chronic diseases such as cancer, autoimmune disorders, diabetes, and cardiovascular diseases continue to rise globally. Biopharmaceutical consumption globally growing, partly driven by a growing need for drugs to treat aging-related and chronic diseases. The growing adoption of technological advancement for drug discovery in complex diseases is the key factor supporting the growth of the market globally. According to the World Health Organization (WHO), in August 2023, HPV infection caused about 5.0% of all cancers globally, with an estimated 625 600 women and 69 400 men getting HPV-related cancer each year. Women living with human immunodeficiency virus (HIV) are six times more likely to develop cervical cancer compared to women without HIV. Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced stages. Market players are continuously focusing on the introduction of drugs for chronic diseases. For instance, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Segmental Outlook

The global biopharmaceuticals market is segmented by product type, service, and application. Based on the product type, the market is sub-segmented into monoclonal antibodies, recombinant growth factors, purified proteins, vaccines, hormones, gene therapies, and others (interferon, synthetic immunomodulators). Based on the service, the market is sub-segmented into laboratory testing, customer proprietary testing, and compendial and multi-compendial laboratory testing. Further, based on application, the market is sub-segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, cardiovascular diseases, neurological diseases, and other (hormonal disorders). Among the applications, the oncology sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of oncology drugs including a wide range of medications such as targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies to treat cancer.

The Vaccines Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biopharmaceuticals Market

Among the product types, the vaccines sub-segment is expected to hold a considerable share of the global biopharmaceutical market. The segmental growth is attributed to an increase in the integration of nanotechnology, gene-based assays, next-generation sequencing technologies, and genetic engineering in the process of vaccine development is expected to enhance the revolutionary potential of novel vaccine types. Nucleic acid vaccines, mRNA vaccines, vector vaccines, and biomaterial-based vaccines are recent trends in the revolutionization of vaccines based on their potential to address issues of existing technology. For instance, in September 2023, Pfizer Inc. and BioNTech SE announced that the US FDA approved the supplemental biologics license application for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.

Regional Outlook

The global biopharmaceuticals market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to a strong base of healthcare facilities, and the availability of advanced treatment options that specifically target the underlying causes of these complex diseases, improved therapeutic outcomes, and enhanced patient care in this region.

The North American region is Expected to Grow at a Significant CAGR in the Global Biopharmaceuticals Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to a rise in the adoption and availability of biopharmaceuticals for disease treatment and a surge in disease diagnosis awareness. Demand for local and imported pharmaceutical products increased as economies grew, and healthcare provision and insurance mechanisms expanded. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in May 2022, in 2021 North America accounted for 49.1% of global pharmaceutical sales compared with 23.4% for Europe. the diversity of pharmaceutical needs as emerging markets increasingly address noncommunicable diseases (NCDs) already prevalent in stronger economies, including diabetes and hypertension, while communicable diseases that afflict many emerging markets such as acquired immunodeficiency syndrome, malaria, and tuberculosis persist. The increase in the global population is also contributing to pharmaceutical consumption.

The market growth is driven by various factors, such as an increase in the elderly population, a surge in the prevalence of chronic diseases such as cancer and diabetes, and an increase in the adoption of biopharmaceuticals globally. Furthermore, a rise in strategic collaborations among biopharmaceutical companies is also anticipated to supplement the growth of the biopharmaceutical industry. The key market player includes AbbVie Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Pfizer Inc. and others.

Market Players Outlook

The major companies serving the biopharmaceuticals market include F. Hoffmann-La Roche AG, Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, IAVI, a nonprofit scientific research organization addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, Darmstadt, Germany, a science and technology company, to develop COVID-19 neutralizing monoclonal antibodies (mAbs).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global biopharmaceuticals market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Johnson and Johnson Service, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. F. Hoffman-La Roche, Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Biopharmaceuticals Market by Product Type
    • 4.1.1. Monoclonal Antibodies
    • 4.1.2. Recombinant Growth Factors
    • 4.1.3. Purified Proteins
    • 4.1.4. Vaccines
    • 4.1.5. Hormone
    • 4.1.6. Gene Therapies
    • 4.1.7. Other (Interferon, Synthetic Immunomodulators)
  • 4.2. Global Biopharmaceuticals Market by Service
    • 4.2.1. Laboratory Testing
    • 4.2.2. Customer Proprietary Testing
    • 4.2.3. Compendial and Multi Compendial Laboratory Testing
  • 4.3. Global Biopharmaceuticals Market by Application
    • 4.3.1. Oncology
    • 4.3.2. Inflammatory and Infectious Diseases
    • 4.3.3. Autoimmune Disorders
    • 4.3.4. Metabolic Disorders
    • 4.3.5. Cardiovascular Diseases
    • 4.3.6. Neurological Diseases
    • 4.3.7. Other(Hormonal Disorders)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East and Africa

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Bayer AG
  • 6.3. Abbott Laboratories
  • 6.4. Allergan, Inc.
  • 6.5. Amgen Inc.
  • 6.6. AstraZeneca plc
  • 6.7. Bayer AG
  • 6.8. Biogen Inc.
  • 6.9. bioMerieux SA
  • 6.10. Bristol-Myers Squibb
  • 6.11. Eli Lilly and Company
  • 6.12. GlaxoSmithKline PlcPharmaceuticals Ltd.
  • 6.13. McKesson Corp.
  • 6.14. Moderna, Inc.
  • 6.15. Merck & Co., Inc.
  • 6.16. Novartis AG
  • 6.17. Novo Nordisk A/S
  • 6.18. Sanofi SA
  • 6.19. Takeda Pharmaceutical Industries, Ltd.
  • 6.20. Vertex Pharmaceuticals

LIST OF TABLES

  • 1. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RECOMBINANT GROWTH FACTORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PURIFIED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL GENE THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHER BIOPHARMACEUTICALS PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 10. GLOBAL BIOPHARMACEUTICALS IN LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL BIOPHARMACEUTICALS IN CUSTOMER PROPRIETARY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL BIOPHARMACEUTICALS IN COMPENDIAL AND MULTI COMPENDIAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BIOPHARMACEUTICALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL BIOPHARMACEUTICALS FOR INFLAMMATORY AND INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL BIOPHARMACEUTICALS FOR AUTOIMMUNE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL BIOPHARMACEUTICALS FOR METABOLIC DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL BIOPHARMACEUTICALS FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL BIOPHARMACEUTICALS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. GLOBAL BIOPHARMACEUTICALS FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 21. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 25. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 26. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 28. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 29. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 30. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 33. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOPHARMACEUTICALS MARKET SHARE BY TRANSACTION MODE, 2022 VS 2030 (%)
  • 2. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 3. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RECOMBINANT GROWTH FACTORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL PURIFIED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL GENE THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHER BIOPHARMACEUTICALS PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022 VS 2030 (%)
  • 11. GLOBAL BIOPHARMACEUTICALS IN LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL BIOPHARMACEUTICALS IN CUSTOMER PROPRIETARY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL BIOPHARMACEUTICALS IN COMPENDIAL AND MULTI COMPENDIAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022 VS 2030 (%)
  • 15. GLOBAL BIOPHARMACEUTICALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL BIOPHARMACEUTICALS FOR INFLAMMATORY AND INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL BIOPHARMACEUTICALS FOR AUTOIMMUNE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL BIOPHARMACEUTICALS FOR METABOLIC DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL BIOPHARMACEUTICALS FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL BIOPHARMACEUTICALS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 21. GLOBAL BIOPHARMACEUTICALS FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 22. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 23. US BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CANADA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. UK BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. FRANCE BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. GERMANY BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. ITALY BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SPAIN BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF EUROPE BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. INDIA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. CHINA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. JAPAN BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 34. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 36. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 37. MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)